Small molecule · Inhibitor of c-Met receptor tyrosine kinase (hepatocyte growth factor receptor) (MET) · developed by ASTRAZENECA
Savolitinib is an orally bioavailable small molecule that binds c-Met receptor tyrosine kinase in an ATP-competitive manner and inhibits its activation, disrupting c-Met signal transduction. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05009836 | Phase 3 | Non-small Cell Lung Cancer | Active not recruiting | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-small Cell Lung Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →